AB Science SA

AB Science operates with a negative equity position of EUR -23.8 million and a debt-to-equity ratio of -0.78, indicating a leveraged capital structure with liabilities exceeding assets. The company’s liquidity is assessed as medium, with a current ratio of 0.71, suggesting limited short-term liquidity to cover immediate obligations. Free cash flow is negative at EUR -7.3 million, driven by high R&D and operational expenditures, while operating cash flow remains modest at EUR 0.5 million. Profitability metrics reveal significant underperformance relative to industry norms. The company reported a net loss of EUR -7.8 million and an operating loss of EUR -6.1 million, with a return on assets of -33.8% and a return on equity of 32.97% due to negative equity. These figures contrast sharply with the median ROIC and EBITDA margins for the Pharmaceuticals industry, where positive returns are typically expected. Geographically, AB Science is present in the United States and Europe, with operations through its subsidiary AB Science USA LCC. However, the company does not disclose segment-specific revenue breakdowns, limiting visibility into geographic or product concentration risks. Growth prospects remain constrained, with revenue at EUR 10.7 million in the latest period and analyst estimates projecting only modest growth to EUR 1.1 million in the next fiscal year. The company’s reliance on R&D for long-term growth exposes it to clinical trial risks and regulatory delays, which could further strain its cash flow. Risk factors include liquidity constraints, with net cash negative after subtracting total debt, and a high probability of continued dilution if the company requires additional capital to fund operations. The company’s equity position is further weakened by a long-term debt of EUR 18.5 million, which could increase financial leverage if not offset by revenue growth. Recent filings and transcripts highlight ongoing R&D efforts for Masitinib and other tyrosine kinase inhibitors, but no material events have been disclosed that would significantly alter the company’s financial trajectory. Analysts have assigned a uniform price target of EUR 2.70, reflecting limited upside potential in the near term.